COL18A1 and Thrombocytopenia: Given the patient’s chronic thrombocytopenia and increased thrombosis risk during prolonged hospitalization, recombinant human endostatin was selected over estrogen/progestin therapy or thalidomide to minimize complications such as bone marrow suppression or thrombosis.